Article

Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylation

2024-09-27

Abstract excerpt

Despite adjuvant treatment with endocrine therapies, estrogen receptor-positive (ER+) breast cancers recur in a significant proportion of patients. Recurrences are attributable to clinically undetectable endocrine-tolerant persister cancer cells that retain tumor-forming potential. Therefore, strategies targeting such persister cells may prevent recurrent disease. Using CRISPR-Cas9 genome-wide knockout screening i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 51e8f61f-a966-5438-abc4-1e68f7c258a4
DOI: 10.1101/2024.09.26.615177

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Endocrine persistence in ER+ breast cancer is accompanied by metabolic vulnerability in oxidative phosphorylationDOI 10.1101/2024.09.26.615177Read

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy–Tolerant Persister Cells in ER+ Breast CancerSemantic proximity Read

Metabolic orchestration of drug-tolerant persister cells in cancerSemantic proximity Read

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategiesSemantic proximity Read

AMPK activation by metformin promotes survival of dormant ER+ breast cancer cellsSemantic proximity Read

Adenosine triphosphate citrate lyase alters cellular myelocytomatosis oncogene signaling and fatty acid oxidation in residual breast cancer tumor tissues after neoadjuvant treatmentSemantic proximity Read

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read

Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrenceSemantic proximity Read

ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancerSemantic proximity Read

Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerSemantic proximity Read

Metabolic reprogramming in breast cancer results in distinct mitochondrial bioenergetics between luminal and basal subtypesSemantic proximity Read

Single-cell transcriptomics reveals age-specific epithelial evolution and metabolic vulnerability in young breast cancerSemantic proximity Read

Oncogenic memory underlying minimal residual disease in breast cancerSemantic proximity Read